Early prediction of subsequent molecular response to nilotinib in patients with chronic myeloid leukemia: Comparison of the quantification of BCR-ABL1 ratios using ABL1 or GUSB control genes

The molecular monitoring of BCR-ABL1 transcripts is a critical prognostic indicator of treatment response in chronic myeloid leukemia (CML). The quantification of BCR-ABL1 transcripts using ABL1 or GUSB as control genes on the early molecular response (MR) to front-line nilotinib was studied using data from 60 patients with chronic phase CML from the ENEST1st substudy. The impact of BCR-ABL1/ABL1 and BCR-ABL1/GUSB ratios at early timepoints as independent variables on subsequent MR was determined by logistic regression analyses and predictive cut-off values determined by receiver operating curve analyses (ROC).

Source: Journal of Molecular Diagnostics - July 16, 2020 Category: Pathology Authors: Ruth Stuckey, Luis-Felipe Casado, Dolors Colomer, Mar ía Teresa Gómez-Casares, Laura Casas, Valentín García-Gutierrez, José Luis Sastre, Ángel Ramírez-Payer, Ferrán Vall-Llovera, María Ángeles Goñi, Blanca Xicoy, Ana Cristina Godoy, Javier Nú� Tags: Regular Article Source Type: research